WebNov 16, 2024 · The two ChromaDex patents, U.S. Patent Nos. 8,197,807 and 8,383,086, concerned compositions and pharmaceutical formulations of nicotinamide riboside (NR), a vitamin present in cow’s milk, for oral administration. The ChromaDex litigation goes back to September 2024, when ChromaDex filed an action alleging infringement by Elysium’s … WebMar 8, 2024 · ChromaDex also holds two patents covering crystal forms of important intermediates in the production of NR Chloride, one of which was granted in 2024. Signed agreement with Sinopharm Xingsha, a subsidiary of one of China’s largest pharmaceutical companies, to conduct cross-border sales of Tru Niagen® in Mainland China. ...
United States Court of Appeals for the Federal Circuit
WebSep 21, 2024 · The litigation between Elysium Health, ChromaDex, and Dartmouth commenced in September 2024, centered on two Dartmouth patents licensed by ChromaDex—U.S. Patent No. 8,383,086 and U.S.... WebChromaDex is continuously evaluating and investigating potential next generation NAD+ precursors, which are molecules at the forefront of the burgeoning healthy aging category, and currently owns and licenses a robust and secure portfolio of over 60 patents relating to Niagen® (patented NR) and other NAD+ precursors. individual learning plans det
ChromaDex Corp. - ChromaDex Announces Issuance of New U.S. Patent …
WebFeb 22, 2024 · ChromaDex is continuously evaluating and investigating potential next generation NAD+ precursors, which are molecules at the forefront of the burgeoning … WebMar 16, 2024 · ChromaDex currently owns and licenses a robust patent portfolio of over 40 granted patents relating to Niagen® (patented NR) and other precursors of NAD, a molecule at the forefront of the ... WebApr 14, 2024 · The company’s patent rights on isolated nicotinamide riboside (NR) are held by the Trustees of Dartmouth College , are licensed exclusively to ChromaDex , and are commercially embodied in ChromaDex’s Tru Niagen product. individual learning plan eyfs